2025 AHA/ACC Hypertension Guidelines
The 2025 AHA/ACC guidelines establish a universal blood pressure treatment goal of <130/80 mm Hg for all adults, with hypertension now defined as BP ≥130/80 mm Hg, and recommend initiating medication therapy at ≥140/90 mm Hg for all adults or at ≥130/80 mm Hg for those with clinical CVD, stroke, diabetes, CKD, or 10-year PREVENT cardiovascular risk ≥7.5%. 1
Blood Pressure Classification Framework
The 2025 guidelines classify blood pressure as follows 1:
- Normal BP: <120/<80 mm Hg
- Elevated BP: 120-129/<80 mm Hg
- Stage 1 Hypertension: 130-139/80-89 mm Hg
- Stage 2 Hypertension: ≥140/≥90 mm Hg
This represents a significant shift from prior definitions, substantially increasing the prevalence of hypertension in the US population while targeting those at highest cardiovascular risk for intervention.
Medication Initiation Thresholds
Immediate Medication Initiation (≥140/90 mm Hg)
All adults with average BP ≥140/90 mm Hg should start antihypertensive medication immediately alongside lifestyle modifications. 1
Risk-Based Medication Initiation (≥130/80 mm Hg)
For adults with BP 130-139/80-89 mm Hg, medication initiation depends on cardiovascular risk stratification 1:
Start medication immediately if ANY of the following apply:
- Clinical cardiovascular disease (coronary artery disease, heart failure, atrial fibrillation)
- Previous stroke
- Diabetes mellitus
- Chronic kidney disease
- 10-year PREVENT cardiovascular risk ≥7.5%
For lower-risk patients (PREVENT <7.5%): Attempt lifestyle modification for 3-6 months first. If BP remains ≥130/80 mm Hg after this trial, initiate medication therapy. 1
Special consideration for adults ≥80 years: Initiate treatment at ≥130/80 mm Hg when clinical judgment suggests benefits outweigh harms and aligns with patient goals of care. 2
Lifestyle Interventions
Lifestyle modifications are strongly recommended for ALL adults with elevated BP or hypertension 1:
- Maintain or achieve healthy weight
- Follow DASH (Dietary Approaches to Stop Hypertension) eating pattern
- Reduce sodium intake
- Increase dietary potassium intake
- Adopt moderate physical activity program
- Manage stress
- Reduce or eliminate alcohol intake
These interventions form the foundation of hypertension management and should be implemented regardless of medication status.
First-Line Medication Selection
For initial antihypertensive therapy, use thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers (CCB), ACE inhibitors (ACEi), or angiotensin receptor blockers (ARB) as first-line agents. 2
These four drug classes have demonstrated equivalent cardiovascular disease prevention compared to placebo, with similar overall efficacy in preventing CVD events.
Initial Combination Therapy for Stage 2 Hypertension
For all adults with Stage 2 hypertension (≥140/90 mm Hg), initiate therapy with 2 first-line agents of different classes in a single-pill, fixed-dose combination rather than 2 separate pills. 1
This approach improves medication adherence and reduces time to achieve BP control, directly impacting cardiovascular outcomes.
Blood Pressure Monitoring Strategy
Home blood pressure monitoring combined with frequent multidisciplinary team interactions using standardized protocols is essential for improving BP control rates. 1
Critical caveat: Avoid reliance on cuffless devices, including smartwatches, for accurate BP measurements until these devices demonstrate greater precision and reliability. 1
Management of Severe Hypertension
Severe hypertension (>180/120 mm Hg) without acute target organ damage should be managed in the outpatient setting with timely initiation, reinstitution, or intensification of oral antihypertensive medications—not in the emergency department. 1
This represents an important shift away from unnecessary emergency department utilization for asymptomatic severe hypertension.
Team-Based Care Approach
Multidisciplinary team-based care is strongly recommended to address medication access and structural barriers to hypertension control. 1
Team members should include:
- Physicians
- Pharmacists
- Nurse practitioners
- Nurses
- Physician assistants/associates
- Dieticians
- Community health workers
- Other healthcare professionals
This collaborative approach has proven effective in improving hypertension control rates by addressing individual patient needs and reducing barriers to care.
Key Differences from Prior Guidelines
The 2025 guidelines represent an evolution from the 2017 ACC/AHA guidelines, maintaining the lower BP thresholds while refining risk stratification using the PREVENT cardiovascular risk calculator rather than the pooled cohort equations. The emphasis on single-pill combination therapy for Stage 2 hypertension and the explicit recommendation against cuffless devices are notable updates. 1, 3
The overarching principle: High blood pressure is the most prevalent and modifiable risk factor for cardiovascular disease, including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality. Aggressive, guideline-directed management directly reduces morbidity and mortality. 1